BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 15, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 5, 2004
View Archived Issues
NO-donating NSAIDs may attenuate neuroinflammation in Alzheimer's disease
Read More
New insight into curcumin action against amyloid pathology
Read More
Soy derivative phyto SERM relieves menopausal symptoms and improves BMD without side effects
Read More
Novel MAO-B inhibitors developed by Roche researchers
Read More
Merck KGaA describes new derivatives of the kappa opioid agonist asimadoline
Read More
Novel PDE4D inhibitors prepared and tested by Novartis scientists
Read More
New benzimidazole-based gastric antisecretory agents claimed by Altana Pharma
Read More
Mitsubishi Pharma and Sanofi-Synthelabo present new TPK1 inhibitors
Read More
Alcon patent covers new 5-HT2 agonists for glaucoma therapy
Read More
Cytovia researchers identify new caspase activators
Read More
CV Therapeutics initiates approval-enabling study of Ranexa
Read More
Enrollment completed in phase I colorectal cancer study of Cotara
Read More
Organon and Meiji Seika sign Japanese agreement for mirtazapine
Read More
Meiact AS granules launched in Japan
Read More
Remofovir mesylate enters phase II
Read More
Research group to study RPI-78M in MS assays
Read More
Pfizer to use Nektar PEGylation technology in drug development
Read More
Approvable letter for Lumigan-timolol combination
Read More
TRX4 evaluated in new phase I study for psoriasis
Read More
sNDA submission for Merrem for complicated skin and skin structure infections
Read More
VivaGel phase I study moves into third stage of dosing
Read More
La Jolla reaches agreement for phase IV Riquent study
Read More
Targeting IP-10 for IBD: Protein Design Labs characterizes antibody for clinical development
Read More
Novel small molecule immunomodulating agent for eczema/psoriasis therapy
Read More
Potent orally active antiinflammatory agent by Bristol-Myers Squibb
Read More
First evidence of effective mGlu2 receptor potentiators for schizophrenia therapy by Merck
Read More